

		Nivolumab		Placebo		HR (95% CI)
		No. of events/ no. of patients (%)	Median (95% CI), mo	No. of events/ no. of patients (%)	Median (95% CI), mo	
DFS	ITT	175/353 (49.6)	22.0 (17.7–36.9)	213/356 (59.8)	10.9 (8.3–14.0)	0.70 (0.57–0.85)
	PD-L1 ≥1%	56/140 (40.0)	NR (22.1–NE)	85/142 (59.9)	8.4 (5.6–20.0)	0.53 (0.38–0.75)
NUTRFS	ITT	165/353 (46.7)	26.0 (19.5–41.1)	199/356 (55.9)	13.7 (8.4–20.0)	0.71 (0.58–0.88)
	PD-L1 ≥1%	55/140 (39.3)	NR (25.8–NE)	82/142 (57.7)	10.8 (5.7–20.7)	0.54 (0.39–0.77)
DMFS	ITT	135/353 (38.2)	41.1 (26.0–NE)	160/356 (44.9)	29.2 (15.2–NE)	0.73 (0.58–0.92)
	PD-L1 ≥1%	48/140 (34.3)	NR (26.0–NE)	64/142 (45.1)	20.7 (10.8–NE)	0.60 (0.41–0.88)

CI, confidence interval; HR, hazard ratio; NE, not estimable; NR, not reached; PD-L1, programmed death ligand 1.